News & Insights

BioPharma's article on the biotechnology sector's notable resurgence in IPOs quotes Gunderson Boston partner Tim Ehrlich.

Gunderson Dettmer Strategic Transactions and Licensing partner Brendan McCarthy hosted the webinar “’What’s Market’ in University Licenses in the Life Sciences Industry” to discuss the key economic terms in university license agreements.

Leading health and wellness platform, Hims & Hers, announces its definitive agreement to acquire Europe-based digital health platform, ZAVA

Cambridge-based biopharmaceutical company pioneering RNAi-based medicine, City Therapeutics, announces its $ 1 billion strategic collaboration with Biogen Inc., a company focused on pioneering innovative science to deliver new medicines

Austin-based biotechnology developer, BioReNuva, announces its newest investment from leading specialty chemical supplier for the beauty and personal care industry, The Hallstar Company

Gunderson Dettmer announces the addition of Life Sciences Partner, Adrian Rich, based in the Northern California offices

Gunderson Dettmer's Life Sciences Group participated across events during the 2024 JPM Healthcare Conference. The JP Morgan Healthcare Conference is the largest and most informative healthcare investment symposium, which connects global industry leaders, emerging fast-growth companies, innovative technology creators, and investment community members.

LMG Life Sciences recognizes Gunderson Dettmer for its market-leading support for venture-backed and public life sciences companies and the venture and growth equity funds investing in that industry around the world.